Amgen Inc., Eli Lilly and Company & GlaxoSmithKline plc. are dominating the Global Migraine Treatment Market in 2019

Global Migraine Treatment Market is expected to grow with the CAGR of 12.4% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access full Report@ https://www.databridgemarketresearch.com/reports/global-migraine-treatment-market

Global migraine treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global migraine treatment market are introducing strong range of drugs provider along with launching new drugs and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • in March, 2020 GlaxoSmithKline plc has received FDA approval for Advil Dual Action with acetaminophen as an over the counter product for pain relief. Acetaminophen is used for making migraine treatment drugs. This approval has helped the company to strengthen its migraine treatment product portfolio.

Amgen Inc. is the dominating player in global migraine treatment market. The other key players existing in the market includes Eli Lilly and Company, AstraZeneca, Amgen Inc., Allergan, Pfizer Inc., GlaxoSmithKline plc., Biohaven Pharmaceuticals, Teva Pharmaceuticals USA, Inc., Bausch Health Companies Inc., Abbott, Dr. Reddy’s Laboratories Ltd., Lundbeck, Merck Sharp & Dohme Corp.(a subsidiary of Merck& Co. Inc.), Novartis AG, Otsuka Pharmaceutical Co., Ltd.( A Subsidiary of Otsuka Holdings Co., Ltd), Catalent, Inc, AOBiome Therapeutics, Bayer AG, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., Zosano Phamra Corporation, Impel NeuroPharma, Inc., Allodynic Therapeutics, LLC, Boehringer Ingelheim International GmbH among others.

Migraine Treatment Market Amgen Inc.

Amgen Inc. headquarter is in California, U.S. was founded in 1980 mainly focuses on areas of high unmet medical needs and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's health. The company has operates in single business segment human therapeutics. The company also has wide product portfolio such as Aimovig, Aranesp, Blincyto, Corlandor, Enbrel, Epogen, Evenity, Imlygic, Kanjinti, Kyprolis, Mvasi, Neulasta, Neupogen, Nplate, Otezla, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Xgeva, in which Aimovig is the market focused category.   

  • In May, 2018 Amgen received FDA approval for Aimovig which is an preventive treatment of migraine in adults. Aimovig acts by blocking calcitonin gene-related peptide receptor (CGRP-R). This product approval has increased the company’s product portfolio and hence aided on to its revenue.

The company has wide presence across North America, South America, Asia, Europe, Middle East and Africa. The company also has various subsidiary companies such as Alantos Pharmaceuticals Holdings (U.S.), Amgen Canada Inc (U.S.), Amgen (Europe) GmbH (Switzerland), Amgen GmbH Germany (Germany), Amgen Holding No. 1 Limited (Bermuda), and Amgen K-A, Inc.(Delaware) among others

Eli Lilly and Company

Eli Lilly and Company headquartered in Indiana, U.S. was founded in 1876. The company engaged in the production and trading of high quality medicines that comes under the human pharmaceutical products. The company provides historic medicines, current medicines, in which current medicines is the market focused product category.

  • In June 2019, Eli Lilly and Company received FDA approval for Emgality which has been approved as one of the first first calcitonin gene related peptide (CGRP) antibody for the treatment of migraine. This approval has increased the company’s product portfolio.

The company has wide presence across Americas, Asia-Pacific, and Europe. The company also has various subsidiary companies such as Alnara Pharmaceuticals, Inc. (U.S.), AME Torreview LLC (U.S.), Andean Technical Operations Center (Peru), Dista-Produtos Quimicos & Farmaceuticos, LDA (Portugal), E L Management LLC (U.S.) among others.

GlaxoSmithKline plc.

GlaxoSmithKline plc. Headquartered in London, U.K. was founded in 1715. The company engaged in providing high-quality healthcare products to the consumers. The company is engaged in providing wide range of product categories such as our prescription medicines, our vaccines, our consumer healthcare products, viv healthcare, stiefel dermatology in which our consumer healthcare products, our prescription medicines are the market focused product categories.

  • In August, 2019 GlaxoSmithKline plc. Completed transaction with Pfizer to form a world leading consumer health care joint venture. This has helped the company to lay its foundation for pharmaceutical in consumer healthcare which involves drugs for migraine treatment.

The company has wide presence across Americas, Asia-Pacific, Europe, Middle East and Africa. The company also has various subsidiary companies such as Glaxo Operations UK Limited(U.K.), GlaxoSmithKline Capital Inc (U.S.), Corixa Corporation (U.S.), GlaxoSmithKline Pharmaceuticals SA (Belgium) and Tesaro, Inc.(U.S.) among others.